$ITCI
Intra-Cellular Therapies, Inc. Stock $itci

$itci Overview Financials Valuation SEC Filings Company Website

2024 Q4 Form 10-Q Financial Statement

#000162828024044196 Filed on October 30, 2024

Income Statement

Concept	2024 Q4	2024 Q3	2023 Q3
Revenue		$175.4M	$126.2M
YoY Change		39.0%	75.56%
Cost Of Revenue		$15.30M	$9.100M
YoY Change		68.18%	55.56%
Gross Profit		$160.1M	$117.0M
YoY Change		36.81%	77.22%
Gross Profit Margin		91.27%	92.73%
Selling, General & Admin		$132.1M	$105.2M
YoY Change		25.57%	19.04%
% of Gross Profit		82.53%	89.91%
Research & Development		$66.82M	$41.55M
YoY Change		60.82%	24.87%
% of Gross Profit		41.74%	35.51%
Depreciation & Amortization		$138.0K	$130.0K
YoY Change		6.15%	-23.53%
% of Gross Profit		0.09%	0.11%
Operating Expenses		$214.2M	$155.9M
YoY Change		37.42%	22.26%
Operating Profit		-$38.85M	-$29.71M
YoY Change		30.75%	-46.59%
Interest Expense		$12.90M	$5.500M
YoY Change		134.53%	159.19%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income		-$25.95M	-$24.22M
YoY Change		7.16%	-54.74%
Income Tax		$374.0K	$43.00K
% Of Pretax Income
Net Earnings		-$26.32M	-$24.26M
YoY Change		8.52%	-54.66%
Net Earnings / Revenue		-15.01%	-19.23%
Basic Earnings Per Share		-$0.25	-$0.25
Diluted Earnings Per Share		-$0.25	-$0.25
COMMON SHARES
Basic Shares Outstanding	106.0M shares	105.7M shares	96.09M shares
Diluted Shares Outstanding		105.8M shares	96.14M shares

Balance Sheet

Concept	2024 Q3	2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.007B	$493.0M
YoY Change	104.16%	-25.83%
Cash & Equivalents	$464.3M	$99.40M
Short-Term Investments	$542.3M	$393.6M
Other Short-Term Assets	$96.02M	$63.80M
YoY Change	50.5%	39.06%
Inventory	$23.54M	$42.99M
Prepaid Expenses
Receivables	$145.6M	$102.7M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$1.272B	$702.4M
YoY Change	81.05%	-7.55%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.005M	$1.789M
YoY Change	12.07%	-14.16%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$6.219M	$86.00K
YoY Change	7131.4%	0.0%
Total Long-Term Assets	$52.71M	$15.24M
YoY Change	245.92%	-31.49%
TOTAL ASSETS
Total Short-Term Assets	$1.272B	$702.4M
Total Long-Term Assets	$52.71M	$15.24M
Total Assets	$1.324B	$717.7M
YoY Change	84.55%	-8.23%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$10.34M	$10.61M
YoY Change	-2.59%	-25.36%
Accrued Expenses	$155.8M	$92.50M
YoY Change	68.41%	46.38%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$166.1M	$103.1M
YoY Change	61.13%	33.18%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$13.51M	$13.90M
YoY Change	-2.83%	-27.48%
Total Long-Term Liabilities	$13.51M	$13.90M
YoY Change	-2.83%	-27.48%
TOTAL LIABILITIES
Total Short-Term Liabilities	$166.1M	$103.1M
Total Long-Term Liabilities	$13.51M	$13.90M
Total Liabilities	$179.6M	$117.0M
YoY Change	53.54%	21.13%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.675B	-$1.589B
YoY Change	5.44%	10.82%
Common Stock	$2.818B	$2.191B
YoY Change	28.65%	3.12%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$1.145B	$600.7M
YoY Change
Total Liabilities & Shareholders Equity	$1.324B	$717.7M
YoY Change	84.55%	-8.23%

Cashflow Statement

Concept	2024 Q3	2023 Q3
OPERATING ACTIVITIES
Net Income	-$26.32M	-$24.26M
YoY Change	8.52%	-54.66%
Depreciation, Depletion And Amortization	$138.0K	$130.0K
YoY Change	6.15%	-23.53%
Cash From Operating Activities	-$26.53M	-$25.27M
YoY Change	4.97%	-52.63%
INVESTING ACTIVITIES
Capital Expenditures	$696.0K	$270.0K
YoY Change	157.78%	-330.77%
Acquisitions
YoY Change
Other Investing Activities	-$208.5M	-$19.90M
YoY Change	947.77%	-118.72%
Cash From Investing Activities	-$209.2M	-$20.17M
YoY Change	937.2%	-119.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	6.734M	2.580M
YoY Change	161.01%	-54.37%
NET CHANGE
Cash From Operating Activities	-26.53M	-25.27M
Cash From Investing Activities	-209.2M	-20.17M
Cash From Financing Activities	6.734M	2.580M
Net Change In Cash	-229.0M	-42.86M
YoY Change	434.28%	-173.3%
FREE CASH FLOW
Cash From Operating Activities	-$26.53M	-$25.27M
Capital Expenditures	$696.0K	$270.0K
Free Cash Flow	-$27.22M	-$25.54M
YoY Change	6.58%	-52.02%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-36274
	dei	Entity Registrant Name EntityRegistrantName	INTRA-CELLULAR THERAPIES, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	36-4742850
	dei	Entity Address Address Line1 EntityAddressAddressLine1	135 Route 202/206, Suite 6
	dei	Entity Address City Or Town EntityAddressCityOrTown	Bedminster
	dei	Entity Address State Or Province EntityAddressStateOrProvince	NJ
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	07921
	dei	City Area Code CityAreaCode	646
	dei	Local Phone Number LocalPhoneNumber	440-9333
	dei	Security12b Title Security12bTitle	Common Stock
	dei	Trading Symbol TradingSymbol	ITCI
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	106017103	shares
CY2024Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	464312000	usd
CY2024Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	14011000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	12928000	usd
CY2024Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	105998786	shares
CY2024Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	105998786	shares
CY2024Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	175375000	usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	126173000	usd
CY2024Q3	itci	Cost Of Product Sales CostOfProductSales	15304000	usd
CY2023Q3	itci	Cost Of Product Sales CostOfProductSales	9129000	usd
CY2024Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	132101000	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	105207000	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-26324000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-24258000	usd
CY2024Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.25
CY2024Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.25
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	96143083	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	96143083	shares
	dei	Entity Central Index Key EntityCentralIndexKey	0001567514
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	147767000	usd
CY2024Q3	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	542250000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	350174000	usd
CY2024Q3	us-gaap	Restricted Cash Current RestrictedCashCurrent	1750000	usd
CY2023Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	1750000	usd
CY2024Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	145608000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	114018000	usd
CY2024Q3	us-gaap	Inventory Net InventoryNet	23539000	usd
CY2024Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	66819000	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	41550000	usd
CY2024Q3	us-gaap	Operating Expenses OperatingExpenses	214224000	usd
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	155886000	usd
CY2024Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-38849000	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-29713000	usd
CY2024Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	12899000	usd
CY2023Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	5498000	usd
CY2024Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-25950000	usd
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.25
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.25
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.57
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.57
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-24258000	usd
CY2024Q3	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	2297000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	149517000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	150365000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	30523000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	11647000	usd
CY2024Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	94272000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	42443000	usd
CY2024Q3	us-gaap	Assets Current AssetsCurrent	1271731000	usd
CY2024Q3	us-gaap	Inventory Noncurrent InventoryNoncurrent	30479000	usd
CY2023Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	38621000	usd
CY2024Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	6219000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	7293000	usd
CY2024Q3	us-gaap	Assets Assets	1324445000	usd
CY2023Q4	us-gaap	Assets Assets	728295000	usd
CY2024Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	10338000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	11452000	usd
CY2024Q3	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	51540000	usd
CY2023Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	27944000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	667799000	usd
	us-gaap	Operating Expenses OperatingExpenses	569153000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-87524000	usd
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	95745641	shares
CY2024Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-24027000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	23000	usd
CY2024Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	1629000	usd
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Period End Date DocumentPeriodEndDate	2024-09-30
CY2024Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2005000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1654000	usd
CY2024Q3	itci	Accrued Customer Programs Current AccruedCustomerProgramsCurrent	70536000	usd
CY2023Q4	itci	Accrued Customer Programs Current AccruedCustomerProgramsCurrent	53173000	usd
CY2024Q3	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	29496000	usd
CY2023Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	27364000	usd
CY2024Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	4203000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3612000	usd
CY2024Q3	us-gaap	Liabilities Current LiabilitiesCurrent	166113000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	123545000	usd
CY2024Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	13506000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	13326000	usd
CY2024Q3	us-gaap	Liabilities Liabilities	179619000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	136871000	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	175000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	175000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	96379811	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	96379811	shares
CY2024Q3	us-gaap	Common Stock Value CommonStockValue	11000	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	10000	usd
CY2024Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	2818137000	usd
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	2208470000	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1674951000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1617160000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	104000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	1144826000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	591424000	usd
CY2024Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1324445000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	728295000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	481629000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	332271000	usd
	itci	Cost Of Product Sales CostOfProductSales	36558000	usd
	itci	Cost Of Product Sales CostOfProductSales	23043000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	366760000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	305144000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	165835000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	129368000	usd
	us-gaap	Operating Expenses OperatingExpenses	457555000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-125284000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	14377000	usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-24215000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-57001000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-110907000	usd
CY2024Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	374000	usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	43000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	188000	usd
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.16
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	790000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-57791000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-111095000	usd
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.16
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.16
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	105768386	shares
CY2024Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	105768386	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	102135530	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	102135530	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	95745641	shares
CY2023Q3	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	933000	usd
CY2023Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-23325000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	22000	usd
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.16
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	105768386	shares
CY2024Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	105768386	shares
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-26324000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-57791000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-111095000	usd
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	1525000	usd
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	2855000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-56266000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-108240000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	656070000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	3640000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	10439000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-44053000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	1492000	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	2581000	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	24000	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	14311000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-24258000	usd
CY2023Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	933000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	600681000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	9989000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	23000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	13843000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-15247000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-534000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	599498000	usd
CY2024Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	543086000	usd
CY2024Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	2093000	usd
CY2024Q2	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	23000	usd
CY2024Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	16370000	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-16220000	usd
CY2024Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-238000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	1144612000	usd
CY2024Q3	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	6734000	usd
CY2024Q3	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	18000	usd
CY2024Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	17489000	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-26324000	usd
CY2024Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	2297000	usd
	us-gaap	Profit Loss ProfitLoss	-57791000	usd
	us-gaap	Profit Loss ProfitLoss	-111095000	usd
	us-gaap	Depreciation Depreciation	399000	usd
	us-gaap	Depreciation Depreciation	392000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	47702000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	37976000	usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	64000	usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	69000	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	6043000	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	5861000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	31590000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	27481000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	3750000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	19066000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	50755000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	16805000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1114000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	218000	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	23596000	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	8172000	usd
	itci	Increase Decrease In Accrued Customer Programs IncreaseDecreaseInAccruedCustomerPrograms	-17363000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	627610000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	8585000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	13226000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-42784000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	430000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	607090000	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	2581000	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	24000	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	14311000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-24258000	usd
CY2023Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	933000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	600681000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	591424000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	9989000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	23000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	13843000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-15247000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-534000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	599498000	usd
CY2024Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	543086000	usd
CY2024Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	2093000	usd
CY2024Q2	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	23000	usd
CY2024Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	16370000	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-16220000	usd
CY2024Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-238000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	1144612000	usd
CY2024Q3	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	6734000	usd
CY2024Q3	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	18000	usd
CY2024Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	17489000	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-26324000	usd
CY2024Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	2297000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	1144826000	usd
	us-gaap	Profit Loss ProfitLoss	-57791000	usd
	us-gaap	Profit Loss ProfitLoss	-111095000	usd
	us-gaap	Depreciation Depreciation	399000	usd
	us-gaap	Depreciation Depreciation	392000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	47702000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	37976000	usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	64000	usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	69000	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	6043000	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	5861000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	31590000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	27481000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	3750000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	19066000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	50755000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	16805000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1114000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	218000	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	23596000	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	8172000	usd
	itci	Increase Decrease In Accrued Customer Programs IncreaseDecreaseInAccruedCustomerPrograms	-17363000	usd
	itci	Increase Decrease In Accrued Customer Programs IncreaseDecreaseInAccruedCustomerPrograms	-9997000	usd
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	2132000	usd
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	2452000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-312000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-1106000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-60099000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-122138000	usd
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	482077000	usd
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	310805000	usd
	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	297568000	usd
	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	369192000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	749000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	268000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-185258000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	58119000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	18816000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	14806000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	543086000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	561902000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	14806000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	316545000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-49213000	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	466062000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	101152000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	2548000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
	us-gaap	Income Taxes Paid IncomeTaxesPaid	1364000	usd
	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	usd
CY2024Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	464312000	usd
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	99402000	usd
CY2024Q3	us-gaap	Restricted Cash Current RestrictedCashCurrent	1750000	usd
CY2023Q3	us-gaap	Restricted Cash Current RestrictedCashCurrent	1750000	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	466062000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	101152000	usd
CY2024Q2	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	7876713	shares
CY2024Q2	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	73.00
CY2024Q2	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	575000000	usd
	itci	Increase Decrease In Accrued Customer Programs IncreaseDecreaseInAccruedCustomerPrograms	-9997000	usd
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	2132000	usd
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	2452000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-312000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-1106000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-60099000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-122138000	usd
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	482077000	usd
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	310805000	usd
	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	297568000	usd
	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	369192000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	749000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	268000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-185258000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	58119000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	543086000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	561902000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	14806000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	316545000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-49213000	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	466062000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	101152000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	2548000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
	us-gaap	Income Taxes Paid IncomeTaxesPaid	1364000	usd
	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	usd
CY2024Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	464312000	usd
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	99402000	usd
CY2024Q3	us-gaap	Restricted Cash Current RestrictedCashCurrent	1750000	usd
CY2023Q3	us-gaap	Restricted Cash Current RestrictedCashCurrent	1750000	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	466062000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	101152000	usd
CY2024Q2	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	7876713	shares
CY2024Q2	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	73.00
CY2024Q2	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	575000000	usd
CY2024Q2	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	543100000	usd
CY2024Q2	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	543100000	usd
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates </span></div>The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Although actual results could differ from those estimates, management does not believe that such differences would be material.
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentration of Credit Risk </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments which potentially subject the Company to concentrations of credit risk consist of accounts receivable, net from customers and cash, cash equivalents and investment securities held at financial institutions. For the nine-month period ended September 30, 2024, 98% of product sales were generated from three major industry wholesalers. </span></div>Three individual customers accounted for approximately 37%, 33%, and 28% as well as 36%, 32%, and 29% of product sales for the nine-month periods ended September 30, 2024 and 2023, respectively. As of September 30, 2024, the Company continues to believe that such customers are of high credit quality.
CY2024Q3	us-gaap	Debt Securities Available For Sale Amortized Cost After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss	563917000	usd
CY2024Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	1674000	usd
CY2024Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	45000	usd
CY2024Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	565546000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Amortized Cost After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss	412570000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	490000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	386000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	412674000	usd
CY2024Q3	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	164000000.0	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	77800000	usd
CY2024Q3	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	1000000.0	usd
CY2024Q3	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	65200000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	165200000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	95100000	usd
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates </span></div>The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Although actual results could differ from those estimates, management does not believe that such differences would be material.
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentration of Credit Risk </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments which potentially subject the Company to concentrations of credit risk consist of accounts receivable, net from customers and cash, cash equivalents and investment securities held at financial institutions. For the nine-month period ended September 30, 2024, 98% of product sales were generated from three major industry wholesalers. </span></div>Three individual customers accounted for approximately 37%, 33%, and 28% as well as 36%, 32%, and 29% of product sales for the nine-month periods ended September 30, 2024 and 2023, respectively. As of September 30, 2024, the Company continues to believe that such customers are of high credit quality.
CY2024Q3	us-gaap	Debt Securities Available For Sale Amortized Cost After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss	563917000	usd
CY2024Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	1674000	usd
CY2024Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	45000	usd
CY2024Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	565546000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Amortized Cost After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss	412570000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	490000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	386000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	412674000	usd
CY2024Q3	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	164000000.0	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	77800000	usd
CY2024Q3	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	66200000	usd
CY2024Q3	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	1000000.0	usd
CY2024Q3	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	65200000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	165200000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	70100000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	95100000	usd
CY2024Q3	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	225100000	usd
CY2023Q4	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	10700000	usd
CY2024Q3	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	30479000	usd
CY2023Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	38621000	usd
CY2024Q3	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	13048000	usd
CY2023Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	4277000	usd
CY2024Q3	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	10491000	usd
CY2023Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	7370000	usd
CY2024Q3	itci	Inventory Current And Noncurrent Net Of Reserves InventoryCurrentAndNoncurrentNetOfReserves	54018000	usd
CY2023Q4	itci	Inventory Current And Noncurrent Net Of Reserves InventoryCurrentAndNoncurrentNetOfReserves	50268000	usd
CY2024Q3	us-gaap	Inventory Net InventoryNet	23539000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	11647000	usd
CY2024Q3	us-gaap	Inventory Noncurrent InventoryNoncurrent	30479000	usd
CY2023Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	38621000	usd
CY2024Q3	itci	Inventory Net Subject To Supplemental Regulatory Procedures InventoryNetSubjectToSupplementalRegulatoryProcedures	8000000.0	usd
CY2023Q4	itci	Inventory Net Subject To Supplemental Regulatory Procedures InventoryNetSubjectToSupplementalRegulatoryProcedures	7700000	usd
CY2024Q3	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	225100000	usd
CY2023Q4	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	10700000	usd
CY2024Q3	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	30479000	usd
CY2023Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	38621000	usd
CY2024Q3	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	13048000	usd
CY2023Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	4277000	usd
CY2024Q3	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	10491000	usd
CY2023Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	7370000	usd
CY2024Q3	itci	Inventory Current And Noncurrent Net Of Reserves InventoryCurrentAndNoncurrentNetOfReserves	54018000	usd
CY2023Q4	itci	Inventory Current And Noncurrent Net Of Reserves InventoryCurrentAndNoncurrentNetOfReserves	50268000	usd
CY2024Q3	us-gaap	Inventory Net InventoryNet	23539000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	11647000	usd
CY2024Q3	us-gaap	Inventory Noncurrent InventoryNoncurrent	30479000	usd
CY2023Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	38621000	usd
CY2024Q3	itci	Inventory Net Subject To Supplemental Regulatory Procedures InventoryNetSubjectToSupplementalRegulatoryProcedures	8000000.0	usd
CY2023Q4	itci	Inventory Net Subject To Supplemental Regulatory Procedures InventoryNetSubjectToSupplementalRegulatoryProcedures	7700000	usd
CY2024Q3	itci	Prepaid Operating Expenses PrepaidOperatingExpenses	31400000	usd
CY2023Q4	itci	Prepaid Operating Expenses PrepaidOperatingExpenses	19465000	usd
CY2024Q3	us-gaap	Deposit Assets DepositAssets	30139000	usd
CY2023Q4	us-gaap	Deposit Assets DepositAssets	15127000	usd
CY2024Q3	itci	Clinical Trial Advances ClinicalTrialAdvances	33389000	usd
CY2023Q4	itci	Clinical Trial Advances ClinicalTrialAdvances	11630000	usd
CY2024Q3	itci	Prefunded Customer Program PrefundedCustomerProgram	5563000	usd
CY2023Q4	itci	Prefunded Customer Program PrefundedCustomerProgram	3514000	usd
CY2024Q3	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	100491000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	49736000	usd
CY2024Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	94272000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	42443000	usd
CY2024Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	6219000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	7293000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P12M
CY2024Q3	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P12M
CY2024Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y8M12D
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y3M18D
CY2024Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0882
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0907
	us-gaap	Operating Lease Cost OperatingLeaseCost	3027000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	2921000	usd
	us-gaap	Variable Lease Cost VariableLeaseCost	1254000	usd
	us-gaap	Variable Lease Cost VariableLeaseCost	1130000	usd
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	1854000	usd
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	1757000	usd
	us-gaap	Lease Cost LeaseCost	6135000	usd
	us-gaap	Lease Cost LeaseCost	5808000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	1112000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	4436000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	4513000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	4573000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	4707000	usd
CY2024Q3	itci	Lessee Operating Lease Liability Payments Due After Year Four LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour	2457000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	21798000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	4089000	usd
CY2024Q3	itci	Prepaid Operating Expenses PrepaidOperatingExpenses	31400000	usd
CY2023Q4	itci	Prepaid Operating Expenses PrepaidOperatingExpenses	19465000	usd
CY2024Q3	us-gaap	Deposit Assets DepositAssets	30139000	usd
CY2023Q4	us-gaap	Deposit Assets DepositAssets	15127000	usd
CY2024Q3	itci	Clinical Trial Advances ClinicalTrialAdvances	33389000	usd
CY2023Q4	itci	Clinical Trial Advances ClinicalTrialAdvances	11630000	usd
CY2024Q3	itci	Prefunded Customer Program PrefundedCustomerProgram	5563000	usd
CY2023Q4	itci	Prefunded Customer Program PrefundedCustomerProgram	3514000	usd
CY2024Q3	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	100491000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	49736000	usd
CY2024Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	94272000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	42443000	usd
CY2024Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	6219000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	7293000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P12M
CY2024Q3	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P12M
CY2024Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y8M12D
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y3M18D
CY2024Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0882
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0907
	us-gaap	Operating Lease Cost OperatingLeaseCost	3027000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	2921000	usd
	us-gaap	Variable Lease Cost VariableLeaseCost	1254000	usd
	us-gaap	Variable Lease Cost VariableLeaseCost	1130000	usd
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	1854000	usd
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	1757000	usd
	us-gaap	Lease Cost LeaseCost	6135000	usd
	us-gaap	Lease Cost LeaseCost	5808000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	1112000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	4436000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	4513000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	4573000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	4707000	usd
CY2024Q3	itci	Lessee Operating Lease Liability Payments Due After Year Four LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour	2457000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	21798000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	4089000	usd
CY2024Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	17709000	usd
CY2024Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	4203000	usd
CY2024Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	13506000	usd
CY2024Q3	us-gaap	Share Based Compensation ShareBasedCompensation	17489000	usd
CY2023Q3	us-gaap	Share Based Compensation ShareBasedCompensation	14311000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	47702000	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4239982	shares
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y2M12D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	11460	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3329460	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	30.74
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y2M12D
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	3329460	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	30.74
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	2968706	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	28.00
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P4Y9M18D
CY2024Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	17709000	usd
CY2024Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	4203000	usd
CY2024Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	13506000	usd
CY2024Q3	us-gaap	Share Based Compensation ShareBasedCompensation	17489000	usd
CY2023Q3	us-gaap	Share Based Compensation ShareBasedCompensation	14311000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	47702000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	37976000	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	28.22
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y2M12D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	34539	shares
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	933601	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	11460	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3329460	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	30.74
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y2M12D
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	3329460	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	30.74
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	2968706	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	28.00
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P4Y9M18D
CY2024Q3	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q3	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q3	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q3	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q3	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q3	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001628280-24-044196-index-headers.html	Edgar Link	pending
0001628280-24-044196-index.html	Edgar Link	pending
0001628280-24-044196.txt	Edgar Link	pending
0001628280-24-044196-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
itci-20240930.htm	Edgar Link	pending
itci-20240930.xsd	Edgar Link	pending
itci-20240930xex106.htm	Edgar Link	pending
itci-20240930xex107.htm	Edgar Link	pending
itci-20240930xex311.htm	Edgar Link	pending
itci-20240930xex312.htm	Edgar Link	pending
itci-20240930xex32.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
itci-20240930_cal.xml	Edgar Link	unprocessable
itci-20240930_def.xml	Edgar Link	unprocessable
itci-20240930_pre.xml	Edgar Link	unprocessable
itci-20240930_lab.xml	Edgar Link	unprocessable
itci-20240930_htm.xml	Edgar Link	completed
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ITCI
Intra-Cellular Therapies, Inc. Stock $itci

2024 Q4 Form 10-Q Financial Statement

#000162828024044196 Filed on October 30, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ITCI Intra-Cellular Therapies, Inc. Stock $itci

2024 Q4 Form 10-Q Financial Statement

#000162828024044196 Filed on October 30, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ITCI
Intra-Cellular Therapies, Inc. Stock $itci